Edwards Lifesciences Corporation $EW Shares Bought by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 306,222 shares of the medical research company’s stock after purchasing an additional 14,600 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Edwards Lifesciences were worth $23,815,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in EW. Brighton Jones LLC acquired a new stake in Edwards Lifesciences in the fourth quarter worth $266,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Edwards Lifesciences by 1.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 100,887 shares of the medical research company’s stock valued at $7,311,000 after acquiring an additional 1,442 shares during the period. Sciencast Management LP bought a new position in shares of Edwards Lifesciences during the first quarter worth about $208,000. Caxton Associates LLP bought a new position in shares of Edwards Lifesciences during the first quarter worth about $370,000. Finally, MBB Public Markets I LLC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $313,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $84.84 on Thursday. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The firm has a market capitalization of $49.23 billion, a PE ratio of 36.57, a P/E/G ratio of 3.49 and a beta of 0.95. The company’s 50 day simple moving average is $84.98 and its 200 day simple moving average is $80.22. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company posted $0.67 EPS. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. National Bankshares set a $92.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 31st. BTIG Research restated a “buy” rating and issued a $103.00 price target (up previously from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Finally, Barclays reaffirmed an “overweight” rating and set a $103.00 target price (up previously from $99.00) on shares of Edwards Lifesciences in a research note on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $94.27.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. This represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 56,805 shares of company stock valued at $4,775,995 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.